The estimated Net Worth of X L.P.Canaan Partners X Llc... is at least $100 Milion dollars as of 28 May 2019. X Llc owns over 400,000 units of IDEAYA Biosciences stock worth over $96,317,811 and over the last 8 years X sold IDYA stock worth over $4,041,304.
X has made over 10 trades of the IDEAYA Biosciences stock since 2016, according to the Form 4 filled with the SEC. Most recently X bought 400,000 units of IDYA stock worth $4,000,000 on 28 May 2019.
The largest trade X's ever made was buying 583,333 units of IDEAYA Biosciences stock on 16 August 2016 worth over $6,999,996. On average, X trades about 170,608 units every 92 days since 2016. As of 28 May 2019 X still owns at least 2,660,713 units of IDEAYA Biosciences stock.
You can see the complete history of X Llc stock trades at the bottom of the page.
Over the last 5 years, insiders at IDEAYA Biosciences have traded over $13,169,580 worth of IDEAYA Biosciences stock and bought 2,220,527 units worth $22,722,236 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Timothy M Shannon a X L.P.Canaan Partners X Llc.... On average, IDEAYA Biosciences executives and independent directors trade stock every 29 days with the average trade being worth of $2,196,906. The most recent stock trade was executed by Jason Throne on 27 June 2024, trading 53,484 units of IDYA stock currently worth $415,571.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IDEAYA Biosciences executives and other stock owners filed with the SEC include: